WILLIAMS AND JENSEN, PLLC for ASTRAZENECA PHARMACEUTICALS LP (FORMERLY ASTRAZENECA PHARMACEUTICALS GROUP)
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report | Apr 14, 2016 | $50,000 | Replaced |
| 1st Quarter - Amendment (this page) | Apr 15, 2016 | $50,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare prescription drug benefit; Drug rebates for Medicare Part D; Part D benefit structure; Independent Payment Advisory Board (IPAB).
| Lobbyist | Covered position, as disclosed |
|---|---|
| JACK STEVEN HART | — |
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | — |
| KARINA LYNCH | — |
| ERIN BOOK MULLEN | — |
| GEORGE OLSEN | — |
Health Issues HCR
21st Century Cures Initiative (House Energy and Commerce Committee) and Innovations for Healthier Americans (Senate Health, Education, Labor and Pensions Committee); possible drug provisions in Continuing Resolution and Consolidated Appropriations Act, 2016; Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Senate Finance Committee chronic disease initiative; Implementation of Precision Medicine Initiative.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | — |
| KARINA LYNCH | — |
| MELINDA M MAXFIELD | — |
| ERIN BOOK MULLEN | — |
| GEORGE OLSEN | — |
| ANTHONY J RODA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.